CIN is often associated with mutations in specific tumour‐suppressor genes and oncogenes (APC, KRAS, PIK3CA, TGF‐β and TP53), which activate crucial pathways involved in the initiation and progression of CRC. The gene discussed is TP53; the disease is neoplasm.